-
1.发明申请SECOND GENERATION VIRUS-LIKE PARTICLES (VLP) FROM EPSTEIN-BARR VIRUSES FOR VACCINATION PURPOSES 有权来自用于疫苗用途的EPSTEIN-BARR病毒的第二代病毒样颗粒（VLP）公开(公告)号：US20140322255A1
公开(公告)日：2014-10-30
申请号：US14366645
申请日：2012-12-28
IPC分类号： A61K39/245
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/525 , A61K2039/5258 , C07K14/005 , C07K14/05 , C07K16/081 , C12N7/00 , C12N15/86 , C12N2700/00 , C12N2710/00041 , C12N2710/10021 , C12N2710/16134 , C12N2710/16171 , C12N2710/16223 , C12N2710/16234 , C12N2710/16242 , C12N2710/16243 , C12N2710/16262 , C12N2710/16634 , C12N2710/16734 , C12N2710/20034 , C12N2800/204
摘要： The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing said EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising said EB-VLPs.
摘要翻译： 本发明涉及基本上不含爱泼斯坦 - 巴尔病毒（EBV）DNA的爱泼斯坦 - 巴尔病毒样颗粒（EB-VLP）。 本发明还涉及包含EBV基因组的多核苷酸a）缺少选自BFLF1基因，BBRF基因，BGRF1基因，BDRF1基因，BALF3基因，BFRF1A基因中的至少一种可表达基因， 和BFRF1基因，以及b）在合适的宿主细胞中产生本发明的EB-VLP。 本发明还涉及包含本发明的多核苷酸的载体和宿主细胞以及制备所述EB-VLP的方法，其疫苗的制备方法，疫苗和包含所述EB-VLP的组合物。
-
公开(公告)号：US20140227305A1
公开(公告)日：2014-08-14
申请号：US13818711
申请日：2011-08-25
IPC分类号： A61K39/245
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5258 , A61K2039/57 , A61K2039/575 , C07K14/005 , C07K2317/569 , C12N7/00 , C12N2710/16223 , C12N2710/16234 , C12N2710/16252 , C12N2710/16262 , C12N2710/16271
摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and/or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.
摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和/或（b）所述颗粒缺乏B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。
-
3.发明公开公开(公告)号：US20240309050A1
公开(公告)日：2024-09-19
申请号：US18274425
申请日：2021-09-01
发明人： Musheng ZENG , Cong SUN , Guokai FENG , Yinfeng KANG
IPC分类号： C07K14/005 , A61K9/51 , A61K39/00 , A61P31/20
CPC分类号： C07K14/005 , A61K9/5169 , A61P31/20 , A61K39/00 , A61K2039/5258 , A61K2039/55555 , A61K2039/575 , C12N2710/16222 , C12N2710/16223 , C12N2710/16234
摘要： Disclosed is a self-assembled nanoparticle containing a gHgL protein of an EB virus, a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a gHgL protein and a first vector subunit, and the second polypeptide comprises a second vector subunit; the first vector subunit is 153-50A1, and the second vector subunit is 153-50B.4PT1; and the gHgL protein is linked to the first vector subunit through a linker. The gHgL protein of the EB virus is displayed on a surface of the self-assembled nanoparticle for the first time. The self-assembled nanoparticle has a larger particle size than the antigen (gHgL), a better antigen residence volume, and a thermal stability comparable to the antigen (gHgL). Moreover, since a larger number of gHgLs are displayed, the self-assembled nanoparticle can strongly stimulate more B cells and induce higher antibody titer.
-
公开(公告)号：US11964006B2
公开(公告)日：2024-04-23
申请号：US16647705
申请日：2018-09-16
申请人： CITY OF HOPE
CPC分类号： A61K39/12 , C07K16/085 , C12N7/00 , A61K2039/55505 , A61K2039/55572 , C07K2317/76 , C12N2710/16222 , C12N2710/16223 , C12N2710/16234
摘要： Disclosed are vaccine compositions comprising a VLP comprising two or more EBV envelope glycoproteins and one or more T cell antigens and methods of preventing or treating EBV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more EBV envelope glycoproteins simultaneously to generate a VLP vaccine. The expression system may include a single vector inserted with two or more nucleic acid sequences that encode two or more EBV envelope glycoproteins linked by one or more linking sequences such that the EBV envelope glycoproteins are co-expressed simultaneously.
-
5.发明申请公开(公告)号：US20180078634A1
公开(公告)日：2018-03-22
申请号：US15558942
申请日：2016-03-16
IPC分类号： A61K39/245 , C12N7/00 , A61K39/12 , G01N33/574
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5256 , A61K2039/5258 , A61K2039/575 , A61K2039/585 , A61K2039/70 , C12N7/00 , C12N2710/16222 , C12N2710/16223 , C12N2710/16234 , C12N2710/16271 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034 , C12N2710/20071 , C12N2760/18122 , C12N2760/18123 , C12N2760/18134 , C12N2760/18171 , G01N33/574 , G01N2333/05
摘要： The present invention relates to prophylactic and/or therapeutic vaccines that contain Newcastle disease virus (NDV) virus-like particles (VLPs) comprising one or more Epstein-Barr Virus (EBV) antigens. In one embodiment, the invention provides a recombinant virus-like particle (VLP) comprising, in operable combination, a) Newcastle disease virus (NDV) matrix (M) protein, and b) one or more Epstein-Barr Virus (EBV) antigens. The invention's prophylactic and/or therapeutic vaccines are useful for preventing and/or treating infection with EBV and/or disease associated Epstein-Barr Virus, such as cancer.
-
公开(公告)号：US20240358813A1
公开(公告)日：2024-10-31
申请号：US18612771
申请日：2024-03-21
申请人： CITY OF HOPE
CPC分类号： A61K39/12 , C07K16/085 , C12N7/00 , A61K2039/55505 , A61K2039/55572 , C07K2317/76 , C12N2710/16222 , C12N2710/16223 , C12N2710/16234
摘要： Disclosed are vaccine compositions comprising a VLP comprising two or more EBV envelope glycoproteins and one or more T cell antigens and methods of preventing or treating EBV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more EBV envelope glycoproteins simultaneously to generate a VLP vaccine. The expression system may include a single vector inserted with two or more nucleic acid sequences that encode two or more EBV envelope glycoproteins linked by one or more linking sequences such that the EBV envelope glycoproteins are co-expressed simultaneously.
-
7.发明公开公开(公告)号：US20230381300A1
公开(公告)日：2023-11-30
申请号：US18032764
申请日：2021-10-20
IPC分类号： A61K39/245 , C12N7/00
CPC分类号： A61K39/245 , C12N7/00 , C12N2710/16223 , C12N2710/16222 , C12N2710/16234 , C12N2710/16252 , A61K2039/5258
摘要： The invention provides a method for manufacturing a HEK293 cell line, which is capable of producing Epstein-Barr virus-like particles (EB-VLPs), as well as the HEK293 cell line obtainable by said method. The invention is further directed to a method for manufacturing EB-VLPs and a composition comprising EB-VLPs obtainable by said method for manufacturing EB-VLPs. Additionally, the invention provides a kit comprising EB-VLPs generated according to the method for manufacturing EB-VLPs. Further, the invention relates to a method for manufacturing a vaccine as well as the vaccine containing EB-VLPs obtainable by said method for manufacturing EB-VLPs.
-
8.发明授权Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes 有权来自爱泼斯坦 - 巴尔病毒的第二代病毒样颗粒（VLP）用于疫苗接种目的公开(公告)号：US09517261B2
公开(公告)日：2016-12-13
申请号：US14366645
申请日：2012-12-28
IPC分类号： A61K39/245 , C12N15/86 , C12N7/00 , A61K39/00 , A61K39/12 , C07K14/005 , C07K16/08
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/525 , A61K2039/5258 , C07K14/005 , C07K14/05 , C07K16/081 , C12N7/00 , C12N15/86 , C12N2700/00 , C12N2710/00041 , C12N2710/10021 , C12N2710/16134 , C12N2710/16171 , C12N2710/16223 , C12N2710/16234 , C12N2710/16242 , C12N2710/16243 , C12N2710/16262 , C12N2710/16634 , C12N2710/16734 , C12N2710/20034 , C12N2800/204
摘要： The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing the EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising the EB-VLPs.
摘要翻译： 本发明涉及基本上不含爱泼斯坦 - 巴尔病毒（EBV）DNA的爱泼斯坦 - 巴尔病毒样颗粒（EB-VLP）。 本发明还涉及包含EBV基因组的多核苷酸a）缺少选自BFLF1基因，BBRF基因，BGRF1基因，BDRF1基因，BALF3基因，BFRF1A基因中的至少一种可表达基因， 和BFRF1基因，以及b）在合适的宿主细胞中产生本发明的EB-VLP。 本发明还涉及包含本发明的多核苷酸的载体和宿主细胞以及制备EB-VLP的方法，其疫苗的制备方法，疫苗和包含EB-VLP的组合物。
-
公开(公告)号：US20160296618A1
公开(公告)日：2016-10-13
申请号：US15077477
申请日：2016-03-22
IPC分类号： A61K39/245 , C07K14/005 , C12N7/00
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/5258 , A61K2039/57 , A61K2039/575 , C07K14/005 , C07K2317/569 , C12N7/00 , C12N2710/16223 , C12N2710/16234 , C12N2710/16252 , C12N2710/16262 , C12N2710/16271
摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.
摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和（b）所述颗粒没有B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞，包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.02 秒)
